The Korea Univertisy Anam Hospital
Seoul, 136-705, South Korea
NCT Number: NCT01549743
This clinical trial aims to assess the pharmacokinetic interaction between celecoxib and rebamipide in healthy male subjects.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Seoul, 136-705, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Celecoxib 200mg will be administered orally twice a day for 3 days
Rebamipide 100mg will be administered orally three times a day for 3 days
Celecoxib plus Rebamipide same way as "arm: celecoxib" and "arm: rebamipide"
Time frame: Day1(0hr), Day2 (0hr), Day3 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hr)
Hanlim Pharm. Co., Ltd.
Industry
Clinical Trial to Assess the Pharmacokinetic Interaction Between Celecoxib and Rebamipide in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07015918
Healthy Male Volunteers
Groningen, Netherlands
View Trial DetailsNCT04534582
Healthy Male Volunteers
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05105425
Healthy Male Volunteers
Paris, France
View Trial DetailsNCT06381869
Healthy Male Volunteers
Clermont-Ferrand, France
View Trial Details